EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Navigating the Paradox of IL‐22: Friend or Foe in Hepatic Health?

Jianqi Qin iD, Weixiong Zhu, Wence Zhou

Journal of Gastroenterology and Hepatology · 2025-06 · 40 (6) · 1393-1408

DOI: 10.1111/jgh.16991 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 13.05.2025. Verfasst von Jianqi Qin und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Second Hospital of Lanzhou University, Department of General Surgery, Lanzhou University Second Clinical Medical College; Key Laboratory of Envir…. Hauptthemen laut MEDLINE: Interleukins, Liver Diseases, Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 172 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Major Science and Technology Projects of Gansu Province, Gansu Provincial Top-notch Talent Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin‐22 (IL‐22), a cytokine from the IL‐10 family produced by T cells and innate lymphoid cells, plays a crucial role in immune responses and tissue regeneration. Its association with liver disease has garnered significant attention; however, its exact impact remains controversial. This review aims to enhance the current understanding of the dual role of IL‐22 in liver disease by exploring its protective and pathogenic effects. First, we provide an overview of IL‐22 biology, including its source, receptors, and signaling pathways. Subsequently, we offer a comprehensive overview of the dual function of IL‐22 in non‐neoplastic liver disease, emphasizing its antiapoptotic and regenerative properties. We also discuss the applicability of the conclusions drawn from studies on nonalcoholic fatty liver disease to metabolic dysfunction‐associated steatotic liver disease. Furthermore, we elaborate on the intricate role of IL‐22 in hepatocellular carcinoma, particularly its influence on the tumor microenvironment, proliferation, and immune evasion. In conclusion, IL‐22 is paradoxical in liver disease, acting as a friend and foe. It is imperative to understand this paradox to develop targeted therapies that capitalize on the beneficial effects of IL‐22 while mitigating its detrimental effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InterleukinsLiver DiseasesLiverInterleukin-22HumansLiver NeoplasmsSignal TransductionCarcinoma, HepatocellularAnimalsNon-alcoholic Fatty Liver DiseaseLiver RegenerationApoptosisTumor MicroenvironmentCell Proliferation

Stichwörter der Autor:innen

IL‐22hepatocellular carcinomaliver fibrosisliver regenerationviral hepatitis

Substanzen

InterleukinsInterleukin-22

Autor:innen und Institutionen

  • The Second Hospital of Lanzhou University, Department of General Surgery, Lanzhou University Second Clinical Medical College; Key Laboratory of Environmental Oncology of Gansu Province, Lanzhou, Gansu, China.

ORCID-Profile: Jianqi Qin

Förderung

  • National Natural Science Foundation of China
  • Major Science and Technology Projects of Gansu Province
  • Gansu Provincial Top-notch Talent Program

Zitieren

APA

Qin, J., Zhu, W., & Zhou, W. (2025). Navigating the Paradox of IL‐22: Friend or Foe in Hepatic Health?. Journal of Gastroenterology and Hepatology, 40(6), 1393-1408. https://doi.org/10.1111/jgh.16991

Vancouver

Qin J, Zhu W, Zhou W. Navigating the Paradox of IL‐22: Friend or Foe in Hepatic Health?. Journal of Gastroenterology and Hepatology. 2025;40(6):1393-1408. doi:10.1111/jgh.16991

BibTeX
@article{Qin2025,
  author = {Qin, Jianqi and Zhu, Weixiong and Zhou, Wence},
  title = {Navigating the Paradox of IL‐22: Friend or Foe in Hepatic Health?},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  volume = {40},
  number = {6},
  pages = {1393--1408},
  doi = {10.1111/jgh.16991}
}
Kostenlos starten →